Journal of Cardiovascular Pharmacology and Therapeutics · 2001 · 41 citations · 34 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyExperimental PharmacologyPreventive CardiologyAtherosclerosis PharmacotherapyCardiac MedicationsCardiovascular DiseaseCardiovascular PharmacologyEndothelial DysfunctionLipid-lowering TherapyAngiotensin Ii Receptor BlockersAntihypertensive PharmacologyAtherosclerotic Cardiovascular Risk ReductionCardiovascular Drug PharmacologyRabbit Cardiovascular Drug EffectsVascular Endothelial DysfunctionVascular Endothelial FunctionVascular Smooth Muscle Relaxation
BACKGROUND: Both angiotensin-converting enzyme inhibitors (ACE-I(s)) and angiotensin receptor blockers (ARB(s)) provide vascular protection. This study was designed to compare ACE-I(s) with widely differing tissue affinity (captopril and quinapril) and an ARB (losartan) on vascular protection against the adverse effects of high cholesterol. METHODS AND RESULTS: Forty-two New Zealand rabbits on a 0.5% cholesterol diet were randomized into control, captopril (10 mg/kg/d), quinapril (0.3 mg/kg/d), and losartan (8 mg/kg/d) groups for 14 weeks. Captopril, quinapril, and losartan significantly attenuated aortic lipid lesions (P=0.001). Captopril and quinapril were more effective than losartan in preserving vascular relaxation. CONCLUSIONS: Captopril, quinapril, and losartan had similar protective effects against atherogenesis. Captopril and quinapril were more effective than losartan in preserving vascular function. Increased bradykinin by ACE inhibition may be responsible for this improved vascular endothelial function.
34
Enzymatic Determination of Total Serum Cholesterol
Charles C. Allain, Lucy S Poon, Cicely S G Chan et al. · Clinical Chemistry · 1974 · 9.2K citations · Full text
Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury
Jerry S. Powell, Jean-Paul Clozel, Rita Müller et al. · Science · 1989 · 1.1K citations
Medicine, Cardiology, Pharmacology +10